Historically, HuNoV research has been hindered by the virus’s exacting growth requirements, which limited experimental capacity. The standard approach relied heavily on virus strains derived directly from the stool samples of infected patients—a resource that is scarce, inconsistent, and unsuitable for large-scale experimental protocols. This bottleneck precluded the establishment of stable viral stocks and hindered systematic studies of viral behavior, pathogenicity, and drug susceptibility. The Baylor team’s recent breakthrough addresses this obstacle by pinpointing and mitigating host cell factors that naturally suppress long-term viral replication within human intestinal enteroid (HIE) cultures.

The advent of HIEs, artificial miniaturized human gut tissues generated from stem cells, marked a pivotal moment for HuNoV research in 2016. These “mini-guts” could be infected, allowing preliminary studies of virus-host interactions, yet the replication within these cultures was ephemeral. After a few viral cycles, the replication plateaued and ultimately ceased, a phenomenon that confined researchers to studying only a single replication round per sample. Without the ability to passage the virus through multiple culture generations, efforts to generate consistent batches of infectious virus were limited.

Addressing this limitation, Baylor researchers conducted an investigative study examining the molecular environment of HIEs upon viral infection. Using RNA sequencing techniques, which quantitatively profile gene expression and cellular responses, the team identified a robust induction of chemokines—immune signaling proteins integral in orchestrating antiviral defense. Among these, CXCL10, CXCL11, and CCL5 were significantly upregulated in infected cells, suggesting that the host’s innate immune pathways are activated and act as intrinsic viral replication brakes within the enteroid system.

Armed with this molecular insight, the researchers hypothesized that interfering with chemokine signaling might alleviate the blockade to viral propagation. They tested TAK-779, a known chemokine receptor antagonist previously developed for other clinical applications, to assess its capacity to disrupt chemokine-mediated antiviral responses. The addition of TAK-779 to HIE cultures resulted in a dramatic enhancement of norovirus replication, enabling the virus to spread extensively among the cells. Remarkably, this allowed for continuous viral passaging over 10 to 15 consecutive rounds—an unprecedented feat in norovirus in vitro cultivation.

This technological leap enables researchers to reliably produce stable and reproducible stocks of infectious HuNoV within laboratory environments, obviating the need for reliance on patient-derived viral samples. Such an innovation opens new avenues for extensive structural studies aimed at characterizing viral architecture, facilitates antiviral drug screening with greater efficiency, and accelerates the rational design and evaluation of vaccine candidates. Notably, the capacity to propagate diverse viral strains in vitro enhances the representativeness and robustness of experimental models.

The study also uncovered intriguing strain-specific differences in how norovirus responds to the chemokine blockade. TAK-779 was effective in boosting the replication of strain GII.3 and facilitated viral growth of strains GII.17 and GI.1. However, it did not enhance replication of the GII.4 strain, which is notorious as the predominant cause of human outbreaks globally. This discrepancy appears to stem from the fact that GII.4 viruses do not elicit significant chemokine secretion within HIEs, resulting in an absence of targets for TAK-779 activity. Consequently, the factors limiting GII.4 growth appear distinct from those affecting other norovirus variants.

In response, the Baylor team is currently refining HIE culture conditions and exploring alternative mechanisms underlying the replication restrictions for GII.4 strains. These ongoing efforts aim to establish optimized in vitro models that can accommodate a broader spectrum of norovirus genotypes, further extending the potential for comprehensive virological inquiries and translational research applications. The ability to cultivate GII.4 strains efficiently in vitro would particularly enhance the relevance of laboratory studies to real-world norovirus epidemiology and pathogenesis.

The collaborative work was led by graduate student Gurpreet Kaur in Dr. Mary Estes’ virology lab, with critical contributions from assistant professor Dr. Sue Crawford and other colleagues. Their combined expertise in molecular virology, microbiology, and gastrointestinal model systems was crucial in overcoming the intricate biological barriers inherent in norovirus culturing. The research was recently published in the peer-reviewed journal Science Advances, reflecting the significant scientific and clinical implications of this breakthrough.

Beyond its immediate research impact, this advancement equips laboratories worldwide with a scalable, reproducible system for HuNoV study. Previously, laboratories lacking access to clinical samples were severely limited in their capacity to contribute to norovirus-specific scientific discovery. This democratization of tools promises to accelerate the pace of norovirus research, filling gaps in understanding viral biology, transmission dynamics, and host-pathogen interactions.

In sum, the Baylor group’s achievement in overcoming host-mediated restrictions to enable sustainable HuNoV replication in human intestinal enteroids signifies a pivotal step forward in infectious disease research. This methodological innovation resolves a decades-long impediment and creates new opportunities to develop effective therapeutic and preventive measures against a globally burdensome pathogen. Their work exemplifies how integrating advanced molecular profiling with targeted pharmacological intervention can unlock fundamental biological challenges, setting a precedent for tackling other stubborn viral pathogens in the future.

Subject of Research: Lab-produced tissue samples

Article Title: Overcoming host restrictions to enable continuous passaging of GII.3 human norovirus in human intestinal enteroids

News Publication Date: 4-Feb-2026

Web References: https://doi.org/10.1126/sciadv.aeb0455

References: Kaur, G., Crawford, S.E., Estes, M.K., et al. Overcoming host restrictions to enable continuous passaging of GII.3 human norovirus in human intestinal enteroids. Science Advances, 2026.

Keywords: Human norovirus, viral replication, human intestinal enteroids, chemokines, TAK-779, in vitro viral culture, antiviral research, gastroenteritis, molecular virology, viral passaging, infectious disease, vaccine development

Recent groundbreaking research conducted by a collaborative team at Baylor College of Medicine and the Duncan Neurological Research Institute at Texas Children’s Hospital provides new insights into the genetic underpinnings of PD. Their studies utilized the laboratory fruit fly to uncover that the interplay between two mutant genes is crucial in instigating neurodegenerative processes. Notably, it appears that the absence of just one copy of the Gba1b gene, recognized as a significant genetic risk factor for PD, does not result in neurological issues. However, when fruit flies lack both copies of Gba1b and one copy of anne—the fruit fly analog of the human gene ATP13A2—neurodegeneration accelerates.

This discovery holds critical implications; the researchers identified multiple individuals diagnosed with PD who carried genetic variants of both ATP13A2 and GBA1. Dr. Hugo Bellen, a prominent figure in the study and Distinguished Service Professor of molecular and human genetics at Baylor, emphasized the necessity of a secondary factor contributing to the development of PD. This revelation sheds light on the complexity of genetic influences in neurodegeneration, indicating that the mere presence of one genetic risk factor alone is insufficient to precipitate the onset of the disease.

In their pursuit of understanding the associated factors, the research team explored genes related to lysosomal functions. Lysosomes are cellular structures essential for degrading and recycling waste materials, and many known risk genes for PD, including GBA1, are intricately linked with lysosomal activity. By utilizing the fruit fly model, the researchers meticulously examined how the Gba1b mutant gene interacts with a variety of genes critical for lysosome functionality. The goal was to uncover whether the presence of mutant forms of Gba1b necessitated a partnership with other lysosomal genes to drive neurodegeneration.

The findings were significant. The research demonstrated that carrying one mutant copy of Gba1b alongside one mutant copy of anne precipitated slow, progressive neurodegeneration in fruit flies. This series of detrimental changes manifested through movement impairments and neuronal loss, along with disturbances in the intricate communication pathways between neurons and glial cells—essential components of the nervous system.

Delving deeper into the underlying mechanisms, the researchers found that Gba1b predominantly operates within glial cells that provide crucial support and protection for neurons. In contrast, anne primarily functions within neurons that send electrical signals vital for maintaining neural networks. This raises a provocative question: how do issues stemming from two distinct cell types converge to provoke neurodegeneration?

Surprisingly, the initial signs of cellular damage presented themselves in glial cells rather than neurons. The glial cells exhibited swelling, detachment from adjacent neurons, and considerable distress, ultimately linked to an accumulation of a lipid molecule known as glucosylceramide (GlcCer) within the lysosomes of glial cells. This accumulation illustrates a failure in the cellular recycling process crucial for maintaining cellular health.

In scenarios where flies carried a mutant version of anne, those neuronal lysosomes struggled to preserve adequate acidity levels. As a consequence, the neurons began generating excess quantities of GlcCer, which subsequently overflowed into the glial cells. This scenario resembles a poorly managed recycling center suddenly inundated with excess garbage from its surroundings, ultimately overwhelming the glial cells that were already under strain.

The repercussions of this accumulation were dire. Glial cells, inundated with waste, experienced severe swelling and structural damage. The lack of robust glial support eventually led to neuron failure, particularly those neurons integral to motor functions and visual processing. The consequences echoed the early onset of Parkinson’s disease, illustrating the gravity of the connection between these two gene mutations and neurodegeneration.

Perhaps one of the most promising revelations of this study was the identification of potential therapeutic avenues aimed at mitigating damage associated with these genetic interactions. Administering ML SA1, a pharmaceutical agent that enhances lysosomal function, successfully restored healthier activity within lysosomes. Furthermore, the use of myriocin, a compound recognized for diminishing GlcCer production, resulted in reduced toxic accumulation. While neither treatment offers an immediate cure for Parkinson’s disease, these findings illuminate potential biological pathways worthy of exploration in the development of future therapies.

This pioneering study involved a wide range of contributors, underscoring a collaborative effort spanning institutions including Baylor College of Medicine, Duncan NRI, Mayo Clinic, and others. It highlights the collaborative nature of modern scientific research, pulling expertise from various fields to tackle complex health challenges.

Looking forward, the implications of this research extend beyond the laboratory. With the rise in neurodegenerative diseases and the increasing prevalence of conditions like Parkinson’s, these findings generate hope. They pave the way for a deeper understanding of how genetic mutations related to lysosomal function can influence neural health. As scientists continue to explore the nuances of genetic interactions, the potential for innovative therapeutic strategies becomes more tangible.

In conclusion, the intricate relationship between genetic risk factors in PD and their cellular ramifications offers a rich field for future inquiries. Further studies will undoubtedly delve into the mechanisms illuminated by this research, potentially leading to enhanced decision-making regarding risk assessment and treatment strategies for individuals at risk of developing Parkinson’s disease.

Subject of Research: Animals
Article Title: Two lysosomal genes ATP13A2 and GBA1 interact to drive neurodegeneration.
News Publication Date: 30-Jan-2026
Web References: Journal
References: 10.1186/s13024-025-00923-z
Image Credits: [Details not disclosed]

Keywords

Alzheimer’s disease is marked by progressive neurodegeneration resulting in cognitive decline and memory loss. Although genome-wide association studies have identified hundreds of genes associated with increased risk, the precise biological mechanisms remain elusive. This knowledge gap hinders the development of effective treatments. To overcome this barrier, the researchers utilized the fruit fly, whose genome surprisingly harbors homologs to a majority of human genes. The fly’s relatively simple nervous system and rapid life cycle provide an ideal model to dissect gene function in a living organism over a compressed timeline, directly linking genetic variations to neurological outcomes.

The research team, spearheaded by neuroscience graduate Dr. Jennifer Deger, employed gene knockout techniques to “turn off” individual risk genes in fruit flies. They systematically evaluated the impacts of these genetic disruptions on brain architecture, neuronal activity, and resilience to environmental stress as the flies aged. This approach allowed the team to gauge how the loss of each gene individually affected brain integrity, synaptic function, and the organism’s capacity to withstand stressors that mirror human neurodegenerative conditions.

One of the pivotal revelations was the discovery that most Alzheimer’s risk genes are actively expressed in the adult fly brain. Notably, subsets of these genes exhibited preferential expression in distinct brain cell types: 24 in neurons—cells responsible for transmitting electrical signals—and 13 in glia, the supportive and regulatory cells within the nervous system. This cell-type specificity illuminates how distinct genetic perturbations might differentially affect neural circuits and brain health, underscoring the intricate cellular interplay implicated in Alzheimer’s pathology.

Functionally, the researchers revealed 50 candidate genes that influence both physical brain structure and neurobiological function. Of these, 18 genes elicited clear signs of neurodegeneration when silenced, manifested as physical deterioration of brain tissue. A standout gene was Snx6, the fly homolog of human SNX32, whose disruption led to pronounced neuronal tissue degradation characterized by the development of necrotic holes. Such findings highlight critical genetic contributors to the structural breakdown seen in Alzheimer’s, advancing our understanding of disease mechanisms at the cellular and molecular scale.

In addition to structural degeneration, the study investigated how gene knockouts affected neuronal electrical activity and behavioral responses to stress. Thirty-five genes proved essential for maintaining normal neuronal electrophysiology, while eight were critical for the flies’ ability to recover from acute stressors such as elevated temperatures and mechanical shocks. Flies with disrupted genes in these categories displayed seizure-like activity or paralysis, paralleling neurological dysfunction and stress vulnerability observed in humans with Alzheimer’s or related dementias.

The investigation further delved into interactions between Alzheimer’s risk genes and toxic protein aggregates ubiquitous in the disease such as amyloid-beta and tau. Twenty-eight genes modulated the flies’ response to these proteins, either exacerbating or mitigating their detrimental effects. This modulation underscores genetic influences in proteinopathy pathways, suggesting that the genetic landscape not only predisposes individuals to disease but also determines the extent of neurotoxic damage from hallmark Alzheimer’s aggregates.

Intriguingly, the team identified distinct biological pathways underlying Alzheimer’s disease susceptibility by clustering genes based on the type of brain deficits they caused—whether structural damage, functional impairment, or diminished stress resilience. This gene grouping corresponded with genetic risk profiles observed in patient populations, revealing causal heterogeneity. Some individuals harbor genetic variants primarily affecting brain morphology, while others bear variants influencing stress response, painting Alzheimer’s as a multifaceted disease with diverse etiologies.

This heterogeneity might elucidate the clinical variability seen in Alzheimer’s patients, explaining why symptom progression and treatment responses differ significantly. Personalized medicine approaches could leverage this knowledge to stratify patients by genetic risk profiles and tailor interventions targeting specific pathological pathways, a transformative concept in neurodegenerative disease management.

To democratize access to their comprehensive data, the researchers launched ALICE (Alzheimer’s Locus Integrative Cross-species Explorer), an interactive web portal that integrates their functional findings with human genetic data. This platform enables scientists worldwide to explore gene-brain relationships, facilitating collaborative research and accelerating discovery of novel therapeutic targets. ALICE represents a vital resource bridging model organism genetics with human disease biology.

The study’s blend of genetic engineering, neurobiology, and systems neuroscience exemplifies the power of integrative experimental design. By dissecting each risk gene’s contribution within the context of an entire organism’s nervous system, the researchers deliver a level of mechanistic insight unattainable through human studies alone. Their findings establish a roadmap for future endeavors aimed at pinpointing molecular nodes amenable to therapeutic intervention.

Supported by a robust framework of NIH grants and philanthropic funding, this work stands at the forefront of Alzheimer’s research. It demonstrates how classical model systems like Drosophila can enlighten human health challenges, reaffirming the translational potential inherent in cross-species genetic analysis. As Alzheimer’s disease continues to impose a staggering societal toll, such innovative research offers renewed hope for unraveling its molecular mysteries and ultimately curbing its devastating impact.

By clarifying the nervous system requirements of Alzheimer’s risk genes, the study invites a paradigm shift—from viewing Alzheimer’s solely as a uniform disease to appreciating it as a constellation of genetically and biologically diverse conditions. This nuanced perspective will be crucial in crafting precision therapeutics and improving outcomes for millions affected by this relentless neurodegenerative disorder worldwide.

Subject of Research: Animals
Article Title: Revealing the nervous system requirements of Alzheimer’s disease risk genes in Drosophila
News Publication Date: 29-Oct-2025
Web References: https://alice.nrihub.org/
References: DOI 10.1016/j.ajhg.2025.10.003
Keywords: Alzheimer’s disease, genetics, neurodegeneration, Drosophila melanogaster, amyloid-beta, tau protein, neurobiology, stress resilience, neuronal function, causal heterogeneity, precision medicine, neurogenetics

Proteins serve as the fundamental workhorses of the biological system, orchestrating myriad cellular processes including tissue growth, metabolic regulation, and immune defense. However, the functionality of proteins is not solely determined by their amino acid sequence; it is extensively modulated by chemical modifications introduced after the protein has been synthesized. These modifications, collectively known as post-translational modifications, involve the covalent attachment of various chemical groups such as phosphates, sugars, or acetyl groups. These PTMs finely tune protein activity, stability, localization, and interactions, thereby dictating the broader cellular response and health outcomes.

PTMs represent critical regulatory nodes within the proteome, directing signaling pathways and cellular machinery in both normal and pathological states. Dysfunctional PTMs have been directly implicated in the etiology of numerous complex diseases, including malignancies, cardiovascular conditions, and degenerative neurological disorders. A mutation in the DNA sequence can disrupt normal PTM patterns by abolishing a modification site, creating ectopic sites, or perturbing the surrounding amino acid environment, thereby derailing protein function and precipitating disease. Therefore, precisely pinpointing PTM sites and understanding mutation-driven alterations are paramount to elucidating disease mechanisms.

Addressing this challenge, the Baylor research team led by Dr. Bing Zhang developed DeepMVP—a deep learning framework meticulously trained to identify PTM sites across the human proteome and predict how mutations reshape these sites. The model was constructed using a novel dataset named PTMAtlas, which represents a comprehensive and rigorously curated collection of 397,524 verified PTM sites derived from the systematic reanalysis of 241 publicly available proteomic datasets. Focusing on six prevalent PTM types, including phosphorylation and glycosylation, PTMAtlas provides a densely annotated resource that dramatically surpasses existing databases in both breadth and accuracy.

DeepMVP’s architecture leverages modern deep neural networks capable of discerning subtle sequence patterns indicative of PTM sites, integrating contextual biochemical properties to enhance predictive power. This approach enables not only precise site identification but also the assessment of how specific amino acid substitutions may enhance or diminish PTM occurrence. The model’s flexibility extends to non-human proteins, effectively predicting PTM sites in viral proteins such as those from the SARS-CoV-2 virus, highlighting its wide utility across biomedical research domains.

Benchmarking DeepMVP against eight state-of-the-art computational tools revealed a clear superiority in performance. Evaluation on a curated set of 235 experimentally validated mutation-PTM pairs demonstrated an impressive 81% accuracy in pinpointing exact PTM sites. More strikingly, DeepMVP correctly predicted the directional change—increase or decrease—of PTM levels caused by mutations in 97% of the cases. These results underscore DeepMVP’s effectiveness in interpreting the functional repercussions of genetic variation at the post-translational level.

The implications of DeepMVP’s predictive capabilities extend far beyond academic interest. By enabling a high-resolution view of how mutations perturb PTM landscapes, this tool offers a powerful platform for the identification of novel therapeutic targets and the design of precision medicine approaches. For example, in cancer biology, understanding aberrant PTM patterns linked to oncogenic mutations may drive the development of targeted inhibitors that restore normal cellular signaling. Similarly, in neurological and cardiovascular diseases, identifying mutation-induced PTM changes could illuminate pathophysiological processes hitherto obscured in genetic studies.

DeepMVP is freely accessible to the global research community, fostering collaborative efforts to exploit its potential across various health disciplines. This open-access availability ensures that scientists investigating disease genetics, drug discovery, and molecular biology can integrate DeepMVP predictions into their workflows, accelerating the translation of genetic insights into tangible clinical interventions.

Complementing the AI model, PTMAtlas stands as a monumental achievement, synthesizing extensive proteomic data into one unified framework. Its creation involved the harmonization of heterogeneous datasets, rigorous quality control measures, and sophisticated bioinformatic pipelines. This assembly provides an unprecedented foundation for future studies in proteomics, molecular evolution, and systems biology, enabling researchers to navigate the complexity of protein modifications with newfound clarity.

The Baylor team acknowledges significant support from various funding bodies, including the National Cancer Institute (NCI) and the Cancer Prevention and Research Institutes of Texas, underscoring the critical role of sustained investment in biomedical innovation. Additionally, computational resources such as the NVIDIA Titan Xp GPU facilitated the model’s training and optimization, reflecting the increasingly interdisciplinary nature of modern bioscience combining biology, computer science, and engineering.

Looking ahead, the researchers envision expanding DeepMVP’s capabilities to encompass additional PTM types and incorporating structural protein information to further refine predictions. Coupled with advances in high-throughput proteomics and functional genomics, such enhancements could revolutionize our capacity to decode the molecular underpinnings of human diseases.

In summary, the deployment of DeepMVP marks a seminal leap in the application of AI to biomedical research, offering a powerful avenue to decode the molecular grammar that links genetic variation to functional protein changes. This work not only deepens our understanding of cellular regulation at the molecular level but also propels the potential for innovative therapeutic strategies targeting post-translational modifications, thus opening new frontiers in precision medicine.

Subject of Research: People

Article Title: DeepMVP: deep learning models trained on high-quality data accurately predict PTM sites and variant-induced alterations

News Publication Date: 26-Aug-2025

Web References: https://www.nature.com/articles/s41592-025-02797-x

References:
Zhang, B., Wang, C., Wen, B., Li, K., Han, P., Holt, M. V., Savage, S. R., Lei, J. T., Dou, Y., Shi, Z., & Li, Y. DeepMVP: deep learning models trained on high-quality data accurately predict PTM sites and variant-induced alterations. Nature Methods, 26 August 2025. DOI: 10.1038/s41592-025-02797-x

Image Credits: Baylor College of Medicine

Keywords: Applied sciences and engineering, Applied mathematics, Computer science, Health and medicine

An international consortium of researchers led by Drs. Hua-Sheng Chiu and Sonal Somvanshi from Baylor College of Medicine, in collaboration with teams from Ghent University, Tsinghua University, and other key institutions, has developed a sophisticated computational platform named BigHorn. This machine-learning tool leverages flexible pattern recognition to predict lncRNA binding sites on DNA and identify their target genes. By moving beyond traditional sequence-matching strategies, BigHorn captures the nuanced “elastic” interactions characteristic of lncRNAs within the cellular milieu, enabling a far more accurate mapping of lncRNA-DNA crosstalk.

Previous studies of lncRNAs have mostly focused on isolated examples and lacked mechanistic depth, leaving a significant knowledge gap regarding their biological relevance and functionality. The current work highlights a paradigm-shifting discovery: many lncRNAs simultaneously engage in dual-level regulation, controlling not just transcriptional activity but also the post-transcriptional stability and translation of their target mRNAs. This duality points to a tightly coupled regulatory circuit, where lncRNAs act as molecular chaperones that govern both gene expression initiation and the fate of the resultant transcripts in a coordinated manner.

The team’s use of BigHorn on an expansive dataset encompassing over 27,000 human tissue and cancer samples unveiled hundreds of such coordinated interactions across various cell types. The implications are vast, suggesting that lncRNAs contribute a sophisticated layer of gene expression fine-tuning that is particularly critical in diseases marked by gene dysregulation, such as cancer. This intricate regulation likely enables cancer cells to maintain robust control over gene networks that fuel their survival and proliferation.

To exemplify this regulatory mechanism, the researchers zeroed in on the lncRNA known as ZFAS1, which has been implicated in multiple cancer types due to its elevated expression levels. BigHorn predicted that ZFAS1 interacts with a broad spectrum of genes; most notably, it regulates the oncogene DICER1 at two pivotal junctures. DICER1 encodes an RNAse crucial for generating microRNAs—small RNA molecules that exert widespread control over mRNA stability and translation. Experimental validation revealed that ZFAS1 not only enhances transcription of the DICER1 gene but also shields its mRNA from degradation, thereby tightly synchronizing DICER1 expression with lncRNA levels.

This robust regulatory motif reveals a vital molecular “dial” where the lncRNA acts as a master controller of gene dosage, impacting entire post-transcriptional networks by modulating key drivers such as DICER1. Given the centrality of microRNAs in gene silencing and cellular homeostasis, this finding underscores how lncRNAs can indirectly influence vast gene expression programs via hierarchical regulatory cascades. Such insights illuminate potential therapeutic targets whereby disrupting lncRNA-mediated coordination could reset aberrant gene circuits in malignancies.

Moreover, this study expands our understanding of lncRNAs beyond their previously assumed fragmented functions, positioning them as integral nodes in cohesively wired gene networks. Their ability to synchronize transcriptional and post-transcriptional gene regulation offers an elegant solution to the complexity of cellular control, especially in dynamic pathological contexts. The dual regulatory role might also provide mechanisms allowing cells to swiftly adapt gene expression outcomes to environmental cues, developmental cues, or stress signals.

Central to the success of this work is BigHorn’s innovative computational methodology. Traditional bioinformatics tools largely depended on strict nucleotide sequence complementarity, often missing the subtlety and conformational flexibility with which lncRNAs interact with chromatin. By employing machine learning techniques sensitive to “elastic” binding patterns, BigHorn achieves a remarkable predictive accuracy that faithfully mirrors biological reality. This advancement sets a new benchmark for future studies seeking to unravel non-coding RNA functions.

Beyond cancer, the findings carry broad implications for developmental biology, aging, and complex diseases. As lncRNAs show tissue-specific expression and are implicated in diverse physiological processes, the discovery of their coordinated regulatory roles opens avenues to decode molecular mechanisms underlying cell fate determination and organismal homeostasis. Researchers now have a powerful tool and conceptual framework to investigate how lncRNAs sculpt gene expression landscapes in both health and disease.

BigHorn is made publicly accessible through the openrna.org platform, inviting the scientific community to explore lncRNA-DNA interactions across organismal systems. By democratizing access to this resource, the authors hope to catalyze novel discoveries that could translate into innovative therapeutic strategies. The interdisciplinary collaboration behind this project exemplifies how computational power, combined with experimental validation, accelerates our grasp of complex genomic regulation.

This landmark study was supported by robust funding from multiple agencies including CPRIT, the European Union’s Horizon 2020 program, the National Cancer Institute, and key institutions across the globe. It leverages data generated from thousands of human samples, illustrating the power of big data in decoding molecular machineries. The contributions of numerous investigators across genetics, molecular biology, oncology, and computational science disciplines reflect the multidisciplinary nature essential to tackling such biological complexity.

In summary, this research heralds a new era in RNA biology, where lncRNAs are appreciated not merely as passive transcripts but as dynamic regulators capable of synchronizing gene expression at multiple regulatory layers. The implications for understanding cellular regulation, particularly in cancer, are profound. As more lncRNAs are studied through the lens of coordinated regulation, we anticipate transformative insights that will reshape molecular medicine and biotechnology.

Subject of Research: Animals
Article Title: Coordinated regulation by lncRNAs results in tight lncRNA-target couplings
News Publication Date: 7-Jul-2025
Web References: https://openrna.org/, http://dx.doi.org/10.1016/j.xgen.2025.100927
References: Cell Genomics, DOI 10.1016/j.xgen.2025.100927
Keywords: Life sciences, Cell biology, Computational biology, Genetics, Molecular biology, Organismal biology, Physiology

Historically, metformin’s primary glucose-lowering role has been attributed to its suppression of hepatic gluconeogenesis—the liver’s production of glucose—thereby reducing blood sugar levels. Additionally, recent studies highlighted the contribution of the gut, with metformin altering intestinal glucose absorption and gut microbiota composition. However, Dr. Makoto Fukuda and colleagues hypothesized that the central nervous system, particularly the brain, might also serve as an essential mediator in metformin’s systemic regulation of glucose metabolism, given the brain’s central role in energy homeostasis.

Focusing on the ventromedial hypothalamus (VMH), a critical brain region involved in systemic energy regulation, the research zeroed in on a small but influential protein, Rap1. This protein acts as a molecular switch within VMH neurons, potentially influencing how the brain senses and regulates glucose balance. The team’s experiments revealed that metformin’s glucose-lowering prowess at clinically relevant, low doses hinges on its ability to inhibit Rap1 activity in the VMH.

To unravel this mechanism, genetically modified mice lacking Rap1 selectively in the VMH were fed a high-fat diet to mirror human type 2 diabetes pathology. Remarkably, when these mice received low-dose metformin, the expected reduction in blood glucose was conspicuously absent, underscoring Rap1’s critical role. Notably, these mice remained responsive to other antidiabetic agents such as insulin and GLP-1 receptor agonists, indicating that the impairment was specific to the metformin-Rap1 axis rather than a broad defect in glucose regulation.

Providing striking support for the brain’s central function, the researchers administered minuscule quantities of metformin directly into the brains of diabetic mice. These intracerebral infusions, measured in doses thousands of times smaller than typical oral administration, elicited a potent hypoglycemic effect. This finding suggests an extraordinary sensitivity of brain circuits to metformin and hints at potential targeted therapies that could harness this pathway with minimal systemic exposure.

Delving into the cellular substrates within the VMH, Dr. Fukuda’s team identified SF1 neurons as pivotal responders to metformin’s action. Electrophysiological recordings from brain slices showed enhanced activity in these neurons following metformin exposure, but importantly, this effect was contingent on the presence of Rap1. In mice genetically devoid of Rap1 specifically in SF1 neurons, metformin failed to activate these cells, reinforcing the protein’s indispensable role in this newly discovered mechanism.

This research revolutionizes the prevailing paradigm of metformin pharmacodynamics. While conventional wisdom emphasized liver and gut tissues as primary sites of action requiring relatively high drug concentrations, the brain’s VMH region appears exquisitely sensitive to metformin at far lower doses. This insight not only broadens understanding of whole-body glucose homeostasis but also unveils new therapeutic targets linked to central nervous system function.

Moreover, the discovery that metformin modulates brain pathways has significant implications beyond glucose control. Metformin has been reported to confer neuroprotective effects, slowing cognitive decline and brain aging in various models. The current study raises the intriguing possibility that Rap1-mediated signaling in the brain may underlie these benefits, warranting intensifying investigations into metformin’s neurobiological impact.

The study’s interdisciplinary team, spanning institutions such as Louisiana State University, Nagoya University, and Meiji University in Japan, combined genetic engineering, pharmacology, and neurophysiology to elucidate these novel mechanisms. Their comprehensive approach, supported by multiple grants from prestigious organizations including the NIH and American Diabetes Association, exemplifies the collaborative spirit driving breakthroughs in metabolic research.

As the global burden of type 2 diabetes continues to climb, advancements that pave the way for more precise interventions are urgently needed. Targeting the brain’s Rap1 pathway could herald a new class of therapies that effectively lower blood glucose with potentially fewer systemic side effects. These findings foster hope for next-generation diabetic treatments tailored to exploit this brain-centric mechanism.

Future studies are set to explore the feasibility of selectively modulating this pathway in humans, including the development of brain-penetrant compounds that mimic metformin’s Rap1 inhibition. Insight into the exact intracellular signaling cascades downstream of Rap1 in SF1 neurons will be pivotal, as will understanding interactions with other metabolic regulators.

In summary, this pioneering research uncovers a crucial role of brain Rap1 in enabling metformin’s antidiabetic effects at low doses, fundamentally reshaping our comprehension of this venerable drug’s mode of action. By integrating neuroscience and metabolic medicine, the study charts a promising course toward innovative diabetes therapies, illuminating the brain’s previously underappreciated contribution to systemic glucose regulation.

Subject of Research: Animals
Article Title: Low-dose metformin requires brain Rap1 for its antidiabetic action
News Publication Date: 30-Jul-2025
Web References: Science Advances article
References: Makoto Fukuda et al., Science Advances, DOI: 10.1126/sciadv.adu3700
Keywords: Diabetes, Metformin, Brain, Rap1, Ventromedial hypothalamus, Glucose metabolism, SF1 neurons, Antidiabetic therapy, Neurobiology, Type 2 diabetes

Cell Painting represents a cutting-edge high-throughput microscopy method that labels multiple cellular components with fluorescent dyes, capturing thousands of images that reveal subtle morphological changes in cells exposed to diverse compounds. According to the study’s corresponding author, Dr. Michael Mancini, professor of molecular and cellular biology and director of Baylor’s Integrated Microscopy Core, this technology allows researchers to observe cellular responses at an unprecedented resolution. By applying custom image analysis pipelines, the team quantified dynamic alterations in cellular structures, providing a detailed phenotypic fingerprint of how each flavonoid interacts with cancer cells.

One of the major challenges of such high-content screening approaches is the sheer volume of data generated. Each Cell Painting experiment can produce over 57,000 confocal microscopy images per plate, a dataset too vast for manual analysis and often requiring substantial computational resources. To overcome this bottleneck, Dr. Mancini’s lab developed SPACe (Swift Phenotypic Analysis of Cells), a novel computational tool capable of individually assessing thousands of cells across numerous experimental plates. Impressively, SPACe can operate efficiently on standard desktop computers, making large-scale drug screening accessible to laboratories regardless of their computational infrastructure.

Applying this powerful methodology, the research team analyzed a library of 244 flavonoid compounds against three widely studied bladder cancer cell lines. Their findings revealed six flavonoids exhibiting significant cytotoxicity, effectively eliminating malignant cells without harming normal bladder cells. Among these were flavopiridol and rotenone, compounds already known for their toxic effects, thereby validating the accuracy of their screening approach. Intriguingly, some flavonoids acted through inducing DNA damage in the cancer cells, while others disrupted mitochondrial function—a critical pathway for cellular energy production—signaling multiple therapeutic mechanisms within this compound class.

Beyond traditional two-dimensional cultures, the study advanced towards more physiologically relevant models, including 3D spheroids and chorioallantoic membrane (CAM) systems, which better mimic tumor architecture and microenvironment. Three of the toxic flavonoids were found to reduce tumor growth in these 3D culture systems as well, reinforcing their potential clinical utility. Significantly, these compounds did not inhibit growth in normal bladder cells, suggesting a degree of cancer cell specificity that could minimize harmful side effects in future therapies.

Among the standout compounds is xanthohumol, a flavonoid derived from hops and found in certain types of beer. The study uncovered that xanthohumol-induced cell death was tightly linked to a reduction in lipid metabolism, particularly a pronounced decrease in the number of lipid droplets within cancer cells. Lipid droplets serve not only as energy stores but also as mediators of cellular signaling and stress responses, marking a novel mechanism of flavonoid-induced cytotoxicity. The possible correlation between xanthohumol consumption and bladder cancer incidence presents a fascinating avenue for epidemiological exploration.

The implications of this research extend well beyond the identification of promising flavonoids. By harnessing the combined power of Cell Painting and SPACe, the Baylor team demonstrated a scalable and precise platform for phenotypic drug discovery that captures the complex heterogeneity of cancer cell populations. This approach allows scientists to classify compounds based on their distinct cellular impact profiles, accelerating the next generation of targeted oncology therapeutics.

Flavonoids themselves are ubiquitously present in fruits, vegetables, and beverages, which raises intriguing possibilities about natural dietary components contributing to cancer prevention or therapy. However, the translation of these in vitro findings to clinical applications requires rigorous validation, including assessment of flavonoid safety, bioavailability, and efficacy in living organisms. The authors emphasize ongoing plans to test these compounds in animal models bearing human bladder tumors and eventually move towards clinical trials to evaluate their therapeutic potential in patients.

The study was a collaborative effort including researchers Jessica Oceguera, Alejandra Rivera Tostado, Christopher D. Candler, Elina Mosa, Kazem Safari, and Maureen G. Mancini. These contributors brought expertise spanning molecular biology, microscopy, and computational analysis, while their institutional support included Baylor College of Medicine and the Texas A&M University’s GCC Center for Advanced Microscopy and Image Informatics.

Funding for this research was provided by multiple prestigious grants, notably from the Cancer Prevention and Research Institute of Texas (CPRIT), the GCC Center for Precision Environmental Health, and the Dan L Duncan Comprehensive Cancer Center. These support mechanisms highlight the critical investment required to facilitate transformative cancer research employing cutting-edge technologies.

As bladder cancer continues to rank as the fifth most common cancer in the United States, causing over 16,000 deaths annually, the need for innovative treatments is urgent. Current clinical practices, while effective at tumor removal and relapse control, often struggle with residual disease that can metastasize. The identification of flavonoids exhibiting selective cytotoxicity against bladder cancer cells offers a hopeful new avenue for improving patient outcomes through less toxic and potentially more effective therapies.

In summary, the marriage of phenotypic screening technologies with natural product libraries exemplified in this study sets a new paradigm in oncology drug discovery. Flavonoid compounds such as xanthohumol exhibit unique cellular interactions that disrupt cancer metabolism and genomic integrity, positioning them as attractive candidates for future therapeutics. This exciting research not only generates a wealth of actionable knowledge but also opens the door to safer, more accessible, and finely tuned cancer treatments, potentially redefining the therapeutic landscape for bladder cancer.

Subject of Research: Human tissue samples

Article Title: A phenotypic screen identifies xanthohumol and other flavonoids as killers of bladder cancer

News Publication Date: 22-Apr-2025

Web References:

• Pharmacological Research – Natural Products Journal
• DOI: 10.1016/j.prenap.2025.100236

Keywords: Human health, Imaging, Microscopy, Organismal biology, Oncology

Dr. Christopher J. Walkey, an assistant professor in integrative physiology at Baylor and the study’s first author, emphasized the importance of adeno-associated viruses (AAVs) in gene delivery. Over the last thirty years, AAVs have gained prominence as a leading vehicle for gene therapy in both preclinical and clinical settings, largely due to their efficiency and safety. This study provides an invaluable tool for researchers, as it delivers a detailed map of AAV delivery across various tissues in mice, which are the standard animal model for preclinical studies. The availability of such data equips researchers, particularly those focusing on muscular diseases, to select vectors that effectively target muscle tissues while minimizing undesired uptake in non-target areas.

The atlas generated as part of this research expands significantly on past efforts, analyzing a broader range of AAVs and tissues than ever before. Using ten distinct AAV vectors, the team studied twenty-two different tissues across both male and female mice. This comprehensive approach was bolstered by the application of advanced fluorescent imaging techniques that allowed for the assessment of gene delivery efficiency at the single-cell level. This combination of methodologies not only sheds light on the functionality of AAVs but also opens new avenues for potential clinical applications in gene therapy, thereby enhancing the therapeutic landscape for conditions that currently have limited treatment options.

Among the intriguing findings of this research was the identification of AAV4, a viral vector previously underexplored, as an efficient carrier of genetic material to endothelial cells in blood vessels and β-cells in the pancreas. AAV4 also demonstrates a low propensity for targeting the liver, which is a common destination for many of the other prevalent AAV varieties. These characteristics position AAV4 as a promising candidate for developing gene therapies aimed at treating diseases affecting the vascular system, an area that has yet to witness significant breakthroughs. Additionally, the vector’s affinity for pancreatic β-cells highlights its potential utility in addressing diabetes, specifically by optimizing insulin production in individuals with metabolic disorders.

The atlas not only assists in the selection of optimal AAV vectors but also provides insights into the off-target effects that various vectors may induce. Understanding where these vectors travel within the body is crucial for minimizing side effects and maximizing therapeutic benefits. Researchers developing gene therapies can leverage this atlas to make informed choices about which vectors to use based on the tissue they are targeting. This resource aims to streamline preclinical studies in mice by allowing researchers to build on a robust foundation of previous research, accelerating the path towards clinical application.

The collaborative nature of this project underscores the importance of teamwork in scientific research. The study was a result of a concerted effort from three distinct groups, brought together under the Phase I initiative of the NIH’s Somatic Cell Genome Editing Consortium. The design and production of the AAVs was spearheaded by researchers at UMass Med, while the Jackson Laboratory team contributed extensively to the fluorescent imaging experiments. Researchers from Baylor College of Medicine played a crucial role in analyzing the distribution of AAV vectors across various tissues, reinforcing the study’s findings through rigorous research practices.

Indeed, the collaborative success illustrated here is a testament to the power of interdisciplinary work in science. The ability to replicate results among different research groups not only enhances the reliability of the findings but also builds confidence in the collective outcomes. The critical funding and support from the NIH played an integral role in making this research possible, highlighting the importance of sustained investment in innovative scientific endeavors.

In closing, the implications of this research extend far beyond the mouse model; it holds the promise of impacting human health through improved gene therapy techniques. Researchers anticipate that the publicly available atlas will serve as a catalyst for further innovation in vector engineering, poised to deliver better gene therapy solutions for a range of human conditions. The transition from preclinical models to real-world applications hinges on our ability to refine these delivery systems, ensuring that gene therapies not only reach their intended targets but also do so safely and effectively.

This study represents a significant forward leap in the field of gene therapy and outlines a pathway for future research. By making crucial insights public, it encourages the broader scientific community to contribute to the ongoing dialogue around gene delivery and therapy. The hope is that through continued collaboration, refinement, and exploration, researchers will unlock new possibilities for treating genetic disorders that have long been considered challenging to address.

As we advance into this new era of medicine, it is the merging of robust scientific research, advanced methodologies, and collaborative spirit that will ultimately pave the way for successful gene therapies. This meticulous work sets the stage for new paradigms in treatment, promising hope for patients with genetic disorders while advancing our understanding of gene therapy’s potential.

Subject of Research: Animals
Article Title: A comprehensive atlas of AAV tropism in the mouse
News Publication Date: 5-Mar-2025
Web References: Molecular Therapy
References: Additional references are not available.
Image Credits: Not provided.
Keywords: Gene therapy, Viral gene delivery, Gene targeting, Genetic medicine, Viral vectors.

In examining mouse models, researchers have identified that the survival of TNBC cells following therapy is intricately linked to the accumulation of lipid droplets enriched with Omega-6 fatty acids. This lipid saturation not only affects the tumor cells but also alters nearby immune cells, particularly neutrophils. These alterations are strikingly significant, as neutrophils, typically tasked with mounting an anti-tumor response, are reprogrammed under these circumstances to facilitate tumor promotion. The study underscores a shift in the interaction dynamics between cancer cells and immune cells that is critical to understanding how tumors can evade treatment.

The findings reveal that tumor cells actively engage in a process where they transfer lipid droplets to the surrounding neutrophils. This transfer is not merely a passive occurrence but a strategic manipulation. By transferring these lipid-rich droplets, the tumor influences the function of neutrophils, effectively reprogramming them from defenders of the immune system to allies of tumor growth. This novel understanding of lipid metabolism presents a paradigm shift in our comprehension of the tumor microenvironment and its role in influencing systemic therapy outcomes.

The principal authors of this study, Dr. Liqun Yu and Dr. Xiang H.-F. Zhang, emphasize the broader implications of their findings. Dr. Zhang notes that while previous research has predominantly focused on fatty acid metabolism as a source of energy for cellular processes, their study introduces the perspective that fatty acids also serve as precursors to immunosuppressive signals utilized by cancer cells. This dual role of fatty acids complicates the landscape of cancer therapy and suggests that manipulating lipid metabolism could offer therapeutic reevaluation.

In practical terms, the researchers highlighted that therapeutic resistance characteristic of TNBC could potentially be reversed by disrupting the formation of lipid droplets in tumor cells. Utilizing pharmacological agents or dietary modifications to inhibit Omega-6 fatty acid intake represents a promising frontline in combating resistance. By adopting a diet low in Omega-6 fatty acids, patients may not only experience resensitization of tumors to existing chemotherapy and immunotherapy regimens but could also mitigate the overall immunosuppressive environment established by the tumor.

The study’s implications extend to dietary recommendations for TNBC patients, aligning with general nutritional advice to lower the intake of red meat, fats, and sodium. However, it specifically brings to light the necessity of focusing on Omega-6 fatty acids, which have been linked to inflammatory pathways and metabolic dysregulation within the tumor microenvironment. This approach might empower patients seeking practical strategies to complement their treatment regimens with dietary choices.

While the study presents compelling preliminary data, further research is essential to evaluate the efficacy of these dietary interventions in clinical settings. The exploration of therapeutic options that specifically block fatty acid accumulation is another exciting avenue that the researchers are pursuing, with the objective of dismantling the immunosuppressive signals that facilitate tumor survival and growth.

These findings are an essential scholarly contribution, supported by robust funding from entities including the U.S. Department of Defense, the National Cancer Institute, and various foundations dedicated to breast cancer research. The study’s depth and breadth highlight the urgent need for comprehensive cancer research that not only probes the biological mechanisms but also considers the translational implications of these discoveries for clinical practice.

The study has garnered attention not only for its scientific rigor but also for the potential it holds in affecting patient outcomes. By translating laboratory findings into actionable insights, researchers hope to bridge the gap between experimental science and real-world clinical applications, ultimately improving the prognosis for patients with TNBC, a subtype that remains challenging due to its aggressive nature and limited treatment options.

In summary, Baylor College of Medicine’s study marks a significant advancement in unraveling the complex interplay between lipid accumulation and immune evasion in triple-negative breast cancer. As researchers continue to delve into the relationship between diet, metabolism, and cancer biology, we can anticipate a new frontier in cancer treatment that prioritizes innovative strategies alongside traditional approaches. This work exemplifies the dedication of scientists to not only understand cancer at a biological level but also to make tangible differences in the lives of those affected by this insidious disease.

Subject of Research: Mechanisms of therapy resistance in triple-negative breast cancer due to lipid accumulation and immune suppression.
Article Title: Tumor-derived arachidonic acid reprograms neutrophils to promote immune suppression and therapy resistance in triple-negative breast cancer.
News Publication Date: March 28, 2025
Web References: Immunity Journal
References: To be determined upon publication.
Image Credits: To be determined upon publication.
Keywords: Triple-negative breast cancer, lipid accumulation, immune suppression, chemotherapy resistance, immunotherapy, Omega-6 fatty acids, tumor microenvironment.

Co-corresponding author, Dr. Chunmei Wang, an assistant professor of pediatrics at the USDA/ARS Children’s Nutrition Research Center at Baylor, provides insight into the study’s findings. Dr. Wang details a pattern observed where body temperatures rise during early pregnancy, return to baseline during late pregnancy, and subsequently increase again during lactation. These fluctuations suggest intricate metabolic programming occurring throughout pregnancy and lactation, shaping maternal behaviors and physiological responses.

Through experimental investigations, the researchers focused on understanding what specific alterations transpire within the brain that influence temperature preference among postpartum female mice. Dr. Wang specifies that the research findings indicate a marked preference for cooler environmental conditions that emerge starting from late pregnancy and persist well into the postpartum phase. Notably, beyond four weeks after weaning, female mice exhibited a consistent decrease in body temperature alongside a newfound preference for cooler settings, illustrating a dramatic departure from their previous warmth-seeking behaviors.

Delving deeper into the biological mechanisms behind these changes, the researchers honed in on the preoptic area (POA) of the brain, a crucial region renowned for its role in monitoring and regulating body temperature. The study unveiled that the shift in temperature preference seen in postpartum females is intricately linked to a notable decline in a specific subset of neurons known for expressing estrogen receptor alpha (ERα), located within the POA. This discovery suggests that reproductive experiences profoundly influence neuronal behavior and, by extension, metabolic functions governing thermoregulation.

Supporting their hypothesis, the research team observed that virgin female mice, genetically modified to lack the estrogen receptor alpha within the ERα neurons of the POA, exhibited a tendency towards cooler temperatures, mirroring the behavior of postpartum females. This intriguing correlation underscores the compelling interplay between hormonal signals and neurological adaptations that configure temperature preference in female mice.

Additionally, the team’s examination of the ERα neurons led to significant revelations regarding how these particular neurons modulate responses to thermal stimuli. They discovered that the ERα neurons possess distinct capabilities for sensing temperature. Some neurons were adept at responding to elevated warmth, while others registered cooler temperatures. This nuanced understanding sheds light on the complex feedback mechanisms within the brain that regulate thermal preferences during the postpartum period, particularly how reproductive changes condition the thermal response pathways.

What stands out is the research team’s conclusion which posits that the capacity of ERα neurons to discern varying temperature conditions is intricately engineered by reproductive history, thereby reshaping behaviors associated with thermal regulation. As a result of these profound shifts in neuronal response, the modified thermal sensations experienced by postpartum females trigger a reallocation of behaviors toward cooler environments—this alteration is indicative of the biological elegance of maternal adaptation in response to new life.

Moreover, the implications of this research extend beyond basic biological understanding; it opens new avenues for exploring therapeutic interventions for conditions related to thermoregulation and metabolic dysfunctions. By associating the physiological changes consonant with reproduction to alterations in brain function and behavior, scientists may be able to inform future studies that delve into the benefits of understanding similar mechanisms in human subjects.

Ongoing research aims to unravel the precise roles of the identified groups of ERα neurons within the POA, with particular attention given to their functional contributions in regulating bodily temperature and diverse thermal preferences. The identification of these groups paves the way for expanding current knowledge regarding thermoregulation, particularly how it interfaces with reproductive biology and maternal instincts—core aspects in addressing challenges from metabolic disorders to reproductive health.

Notably, the collaborative efforts of a diverse team of researchers, including Nan Zhang, Meng Yu, Qianru Zhao, and others, reflect the multidisciplinary nature of this research. The affiliations of these contributors span several prestigious institutions, lending a broader perspective to the investigative rigor behind this study. Each team member brings unique expertise, enhancing the overall comprehension of the metabolic and neurological adaptations during reproductive cycles.

In essence, this study not only underscores the biological intricacies associated with maternal adaptation but also captivates interest due to its potential implications in broader biomedicine. By modulating temperature preferences through neurological pathways, researchers are inching closer to understanding how fundamental biological processes can give rise to behavioral and physical changes aimed at fostering new life.

As scientists build on this foundation, elucidating the mechanisms behind the findings may lead to innovative models informing maternal health practices and designs of therapeutic strategies targeting metabolic issues in wider populations. Altogether, this research serves as a compelling reminder of the delicate interconnections inherent in the body’s design, particularly how reproductive life stages govern not just physiological adaptations but also behavioral frameworks essential for nurturing offspring.

In conclusion, this investigation into the adaptations of postpartum female mice reveals how body temperature regulation is not merely a biological necessity but a sophisticated interplay of hormonal signals, neuronal networks, and environmental interactions that ultimately define maternal behaviors. Such knowledge will undoubtedly add to the evolving narrative surrounding reproductive health and developmental biology while inviting future inquiry into the implications for both human and animal models alike.

Subject of Research: Animals
Article Title: Altered thermal preference by preoptic estrogen receptor alpha neurons in postpartum females
News Publication Date: 3-Feb-2025
Web References: Molecular Metabolism
References: DOI: 10.1016/j.molmet.2025.102108
Image Credits: N/A

Keywords: Pregnancy, Temperature, Body temperature regulation, Estrogen receptors, Metabolism